Bilcare Q1FY26 Results: Net profit falls 16% YoY to ₹13.00 crore

1 min read     Updated on 15 Aug 2026, 07:15 PM
scanx
Reviewed by
Riya DScanX News Team
AI Summary

Bilcare Ltd posted a net profit of ₹13.00 crore in Q1FY26, down 16% YoY, as total income fell 24.7% to ₹16.58 crore. Profit before tax also declined to ₹14.97 crore. Despite the top-line contraction, net margins improved slightly due to cost containment. Equity capital remained stable at ₹23.55 crore.

powered bylight_fuzz_icon
48347111

*this image is generated using AI for illustrative purposes only.

Bilcare Limited reported a net profit of ₹13.00 crore for the quarter ended June 30, 2026, down 15.9% year-on-year from ₹15.49 crore in Q1FY25. The company’s total income from operations contracted sharply by 24.7% to ₹16.58 crore, compared to ₹22.04 crore in the prior year period.

Profit before tax (PBT) also declined, falling 16.6% to ₹14.97 crore from ₹17.97 crore in Q1FY25. The simultaneous drop in both revenue and pre-tax earnings indicates that the profit contraction was primarily operational, stemming from reduced business volumes or pricing pressures rather than one-off tax adjustments or exceptional items.

Financial Highlights

Metric: Q1FY26 (Unaudited): Q1FY25 (Unaudited): Change:
Total Income: ₹16.58 crore ₹22.04 crore -24.7%
PBT: ₹14.97 crore ₹17.97 crore -16.7%
Net Profit: ₹13.00 crore ₹15.49 crore -16.1%

The company’s total comprehensive income for the period stood at ₹13.00 crore, aligning with its net profit figure as no other comprehensive income items were reported. Equity share capital remained unchanged at ₹23.55 crore, while reserves and other equity increased slightly to ₹16.18 crore from ₹15.45 crore in the previous quarter, suggesting retained earnings were added despite the lower current-period profit.

What the Numbers Show

A key observation from the filing is the divergence between the revenue decline and the margin resilience. While total income fell nearly 25%, the net profit margin remained relatively stable at approximately 78.4% of revenue (₹13.00 crore / ₹16.58 crore), compared to 70.3% in Q1FY25 (₹15.49 crore / ₹22.04 crore). This suggests that while volume or top-line growth was weak, the company maintained cost discipline or benefited from fixed-cost leverage, preserving profitability ratios even as sales contracted.

Regulatory Disclosures

The unaudited financial results were filed in compliance with Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The figures have been reviewed by the company’s statutory auditors. Previous periods’ figures have been regrouped wherever necessary to conform to the current presentation format.

The results were approved by the Board of Directors in a meeting held on August 15, 2026. The company’s registered office is located in Pune.

Historical Stock Returns for Bilcare

1 Day5 Days1 Month6 Months1 Year5 Years
+20.00%+25.40%+20.00%+20.58%+20.58%+20.58%

What specific operational factors or market conditions drove the 24.7% contraction in total income for Q1FY26?

How sustainable is the improved net profit margin of 78.4% if revenue volumes continue to decline in subsequent quarters?

Has Bilcare Limited announced any strategic initiatives to reverse the downward trend in business volumes?

Bilcare shareholders approve Ashwini Hasabnis as Independent Director

2 min read     Updated on 24 Jul 2026, 03:54 PM
scanx
Reviewed by
Ashish TScanX News Team
AI Summary

Bilcare Limited shareholders overwhelmingly approved the appointment of Mrs. Ashwini Ashok Hasabnis as an Independent Director for five years. The special resolution passed with 99.94% support, with promoters casting all their votes in favour and public shareholders showing 97.32% support. The process was conducted via remote e-voting between June 23 and July 22, 2026, with Mr. Shekhar Ghatpande serving as scrutinizer.

powered bylight_fuzz_icon
46434261

*this image is generated using AI for illustrative purposes only.

Bilcare Limited shareholders have approved the appointment of Mrs. Ashwini Ashok Hasabnis as a Non-Executive Woman Independent Director for a term of five years. The special resolution received overwhelming support, with 99.94% of votes cast in favour and only 0.06% against, marking a decisive endorsement of the Board’s governance structure. The appointment strengthens the company’s independent oversight capabilities as it continues to operate in the healthcare sector.

The resolution was transacted through a postal ballot process conducted via remote e-voting, compliant with Regulation 44 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The e-voting window remained open from June 23, 2026, at 09:00 A.M. IST to July 22, 2026, at 05:00 P.M. IST. Shareholders holding equity shares on the record date of June 12, 2026, were eligible to vote. Mr. Shekhar Ghatpande, Partner at Ghatpande & Ghatpande Associates, served as the scrutinizer for the process and submitted his report on July 23, 2026.

Voting Results Breakdown

The total number of shares held by eligible shareholders stood at 23,545,231. Of these, 5,994,442 shares voted, representing a participation rate of 25.46%. The promoter group held 7,066,611 shares and cast all 5,861,489 polled votes in favour of the resolution. Public non-institutional shareholders held 16,468,620 shares; of the 132,953 votes polled from this category, 129,387 were in favour and 3,566 were against.

Category Shares Held Votes Polled Votes In Favour Votes Against % Support
Promoter Group 7,066,611 5,861,489 5,861,489 0 100.00%
Public Institutions 10,000 0 0 0 0.00%
Public Non-Institutions 16,468,620 132,953 129,387 3,566 97.32%
Total 23,545,231 5,994,442 5,990,876 3,566 99.94%

As per Section 114 of the Companies Act, 2013, a special resolution requires votes cast in favour to be three times more than those cast against. With 5,990,876 votes in favour versus 3,566 against, the resolution comfortably met this threshold. The scrutinizer’s report confirmed that no invalid votes were recorded during the process.

Governance Implications

The appointment of Mrs. Hasabnis, identified by DIN 07766525, adds to Bilcare’s independent director strength, ensuring compliance with corporate governance norms regarding board composition. The high level of support from both promoter and public shareholders indicates strong confidence in the candidate’s qualifications and the Board’s selection process. The remote e-voting mechanism facilitated broad participation without the need for physical meetings, aligning with regulatory pushes for digital shareholder engagement. The voting results and scrutinizer’s report are available on the company’s website and the portal of MUFG Intime India Pvt. Ltd., the Registrar and Share Transfer Agent.

Historical Stock Returns for Bilcare

1 Day5 Days1 Month6 Months1 Year5 Years
+20.00%+25.40%+20.00%+20.58%+20.58%+20.58%

How will Mrs. Hasabnis's specific expertise influence Bilcare's strategic direction in the evolving healthcare sector?

What impact might the addition of an independent woman director have on Bilcare's ESG ratings and investor appeal?

Does the low participation rate of 25.46% among eligible shareholders signal apathy or a need for improved investor engagement strategies?

More News on Bilcare

1 Year Returns:+20.58%